FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2043628086> ?p ?o ?g. }

• W2043628086 endingPage "1001" @default.
• W2043628086 startingPage "992" @default.
• W2043628086 abstract "Based upon the central role transforming growth factor-beta (TGF-beta) overexpression appears to play in renal fibrotic diseases, we have recently advocated reduction of TGF-beta as a therapeutic target. As part of efforts to determine the strength of this approach, we have undertaken studies to quantitate the effects of currently used and promising therapies in terms of their potential to reduce markers of disease in anti-thymocyte-serum (ATS)-glomerulonephritis in the rat. Here we assess the therapeutic effect of L-arginine supplementation, which has been shown to reduce fibrosis in a number of hypertensive models, given alone or in combination with low protein diet and started 24 hours after disease induction.Glomerulonephritis was induced by intravenous injection of OX-7 monoclonal antibody into 200 g Sprague-Dawley rats. Twenty-four hours later animals were placed in groups that were either untreated, treated with 1% L-arginine in drinking water or 6% protein diets or both. On the fifth day of disease 24-hour urine specimens were collected and systemic blood pressure was measured. On the sixth day rats were anesthetized. Kidneys were perfused, tissue was taken for PAS staining and glomeruli were isolated. Aliquots of glomeruli were used for RNA preparation and for culture to determine 72-hour production of TGF-beta, fibronectin and plasminogen activator-type 1 (PAI-1), which were assayed by ELISA on culture supernatants. Measures of nitrate and nitrite (NOx) production included plasma NOx, urinary NOx and glomerular production of NOx in culture.All disease measures except proteinuria and including matrix accumulation, TGF-beta, fibronectin and PAI-1 production and mRNA expression for TGF-beta, fibronectin and PAI-1 were significantly and similarly reduced by about 50% in groups treated with L-arginine or with low protein diet. Proteinuria was reduced in low protein treated but not in L-arginine supplemented rats. Neither systemic blood pressure nor measures of NO synthesis showed differences between groups that could be attributed to L-arginine supplementation. In contrast, disease-related increases in glomerular production of NOx were markedly reduced by low protein. Combined therapy resulted in small, but statistically significant decreases in most measures of disease.L-arginine supplementation reduces fibrotic disease in ATS-induced glomerulonephritis if started after disease induction. The absence of evidence for increased NO production related to L-arginine supplementation suggests that L-arginine is acting here through different pathways from those demonstrated in hypertensive models of disease. The data support the ideas that TGF-beta reduction is a valid therapeutic target and that quantitation of TGF-beta reduction is a useful approach for comparing antifibrotic drug candidates." @default.
• W2043628086 created "2016-06-24" @default.
• W2043628086 creator A5010680177 @default.
• W2043628086 creator A5036932318 @default.
• W2043628086 creator A5037282171 @default.
• W2043628086 date "2000-03-01" @default.
• W2043628086 modified "2023-09-28" @default.
• W2043628086 title "Tandem antifibrotic actions of L-arginine supplementation and low protein diet during the repair phase of experimental glomerulonephritis" @default.
• W2043628086 cites W1608791497 @default.
• W2043628086 cites W1966388332 @default.
• W2043628086 cites W1975715446 @default.
• W2043628086 cites W1975755598 @default.
• W2043628086 cites W1982707536 @default.
• W2043628086 cites W1984261234 @default.
• W2043628086 cites W1987954100 @default.
• W2043628086 cites W1990802251 @default.
• W2043628086 cites W1993851092 @default.
• W2043628086 cites W1994247359 @default.
• W2043628086 cites W1997677650 @default.
• W2043628086 cites W2000512590 @default.
• W2043628086 cites W2009393201 @default.
• W2043628086 cites W2026275252 @default.
• W2043628086 cites W2031782395 @default.
• W2043628086 cites W2033465719 @default.
• W2043628086 cites W2039626545 @default.
• W2043628086 cites W2043625574 @default.
• W2043628086 cites W2044478331 @default.
• W2043628086 cites W2051819610 @default.
• W2043628086 cites W2055533480 @default.
• W2043628086 cites W2059258621 @default.
• W2043628086 cites W2060335268 @default.
• W2043628086 cites W2066538838 @default.
• W2043628086 cites W2070005444 @default.
• W2043628086 cites W2072558376 @default.
• W2043628086 cites W2076770055 @default.
• W2043628086 cites W2080287320 @default.
• W2043628086 cites W2082261438 @default.
• W2043628086 cites W2091321868 @default.
• W2043628086 cites W2094610390 @default.
• W2043628086 cites W2114696344 @default.
• W2043628086 cites W2120005533 @default.
• W2043628086 cites W2124843985 @default.
• W2043628086 cites W2128520582 @default.
• W2043628086 cites W2145792977 @default.
• W2043628086 cites W2146559746 @default.
• W2043628086 cites W2148365188 @default.
• W2043628086 cites W2335187016 @default.
• W2043628086 cites W2342753235 @default.
• W2043628086 doi "https://doi.org/10.1046/j.1523-1755.2000.00927.x" @default.
• W2043628086 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10720952" @default.
• W2043628086 hasPublicationYear "2000" @default.
• W2043628086 type Work @default.
• W2043628086 sameAs 2043628086 @default.
• W2043628086 citedByCount "34" @default.
• W2043628086 countsByYear W20436280862013 @default.
• W2043628086 countsByYear W20436280862015 @default.
• W2043628086 countsByYear W20436280862017 @default.
• W2043628086 countsByYear W20436280862019 @default.
• W2043628086 countsByYear W20436280862021 @default.
• W2043628086 countsByYear W20436280862022 @default.
• W2043628086 crossrefType "journal-article" @default.
• W2043628086 hasAuthorship W2043628086A5010680177 @default.
• W2043628086 hasAuthorship W2043628086A5036932318 @default.
• W2043628086 hasAuthorship W2043628086A5037282171 @default.
• W2043628086 hasBestOaLocation W20436280861 @default.
• W2043628086 hasConcept C126322002 @default.
• W2043628086 hasConcept C134018914 @default.
• W2043628086 hasConcept C203014093 @default.
• W2043628086 hasConcept C2779561371 @default.
• W2043628086 hasConcept C2779679481 @default.
• W2043628086 hasConcept C2780026642 @default.
• W2043628086 hasConcept C2780091579 @default.
• W2043628086 hasConcept C2780368995 @default.
• W2043628086 hasConcept C2780559512 @default.
• W2043628086 hasConcept C519581460 @default.
• W2043628086 hasConcept C71924100 @default.
• W2043628086 hasConceptScore W2043628086C126322002 @default.
• W2043628086 hasConceptScore W2043628086C134018914 @default.
• W2043628086 hasConceptScore W2043628086C203014093 @default.
• W2043628086 hasConceptScore W2043628086C2779561371 @default.
• W2043628086 hasConceptScore W2043628086C2779679481 @default.
• W2043628086 hasConceptScore W2043628086C2780026642 @default.
• W2043628086 hasConceptScore W2043628086C2780091579 @default.
• W2043628086 hasConceptScore W2043628086C2780368995 @default.
• W2043628086 hasConceptScore W2043628086C2780559512 @default.
• W2043628086 hasConceptScore W2043628086C519581460 @default.
• W2043628086 hasConceptScore W2043628086C71924100 @default.
• W2043628086 hasIssue "3" @default.
• W2043628086 hasLocation W20436280861 @default.
• W2043628086 hasLocation W20436280862 @default.
• W2043628086 hasOpenAccess W2043628086 @default.
• W2043628086 hasPrimaryLocation W20436280861 @default.
• W2043628086 hasRelatedWork W1781372697 @default.
• W2043628086 hasRelatedWork W2020959757 @default.
• W2043628086 hasRelatedWork W2042033030 @default.
• W2043628086 hasRelatedWork W2044943066 @default.
• W2043628086 hasRelatedWork W2070511355 @default.
• W2043628086 hasRelatedWork W2082456910 @default.

• next